Insiders Buying Solid Biosciences And 2 Other Stocks
Insiders Buying Solid Biosciences And 2 Other Stocks
Although U.S. stocks closed mixed on Friday, there were a few notable insider trades.
儘管週五美國股市收盤漲跌互現，但仍有一些值得注意的內幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
當內部人士購買股票時，這表明他們對公司前景充滿信心，或者他們認爲股票很划算。無論哪種方式，這都預示着做多該股的機會。不應將內幕購買視爲做出投資或交易決策的唯一指標。充其量，它可以爲購買決定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的內幕收購。欲了解更多，請查看 本辛加的內幕交易 平台。
Solid Biosciences
固體生物科學
- The Trade: Solid Biosciences Inc. (NASDAQ:SLDB) Director Joseph Edelman acquired a total of 3,410,713 shares an average price of $5.53. To acquire these shares, it cost around $18.86 million. The company's 10% owner RA Capital Nexus Fund, L.P also bought 904,160 shares at an average price of $5.53.
- What's Happening: Solid Biosciences entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $108.9 million private placement.
- What Solid Biosciences Does: Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs.
- 交易：Solid Biosciences Inc.（納斯達克股票代碼：SLDB）董事約瑟夫·愛德曼 共收購了3,410,713股股票 平均價格爲5.53美元。收購這些股票的成本約爲1886萬美元。該公司10％的所有者RA Capital Nexus Fund, L.P還以5.53美元的平均價格購買了904,160股股票。
- 發生了什麼：Solid Biosciences與一批精選的機構認可投資者簽訂了證券購買協議，進行約1.089億美元的私募融資。
- Solid Biosciences 做什麼：Solid Biosciences Inc 是一家生命科學公司。它從事特種藥物和仿製藥的製造。
Champions Oncology
腫瘤學冠軍
- The Trade: Champions Oncology, Inc. (NASDAQ:CSBR) Director Daniel Mendelson acquired a total of 2,000 shares at an average price of $6.27. To acquire these shares, it cost around $12,540.
- What's Happening: Champions Oncology, last month, posted a loss for the second quarter.
- What Champions Oncology Does: Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.
- 交易：Champions Oncology, Inc.（納斯達克股票代碼：CSBR）董事丹尼爾·門德爾森共收購了2,000股股票，平均價格爲6.27美元。收購這些股票的成本約爲12,540美元。
- 發生了什麼：Champions Oncology上個月公佈了第二季度虧損。
- Champions Oncology做什麼：Champions Oncology Inc是一家總部位於美國的公司，致力於開發和銷售先進的技術解決方案和產品，以實現腫瘤藥物的個性化開發和使用。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
AMREP
AMREP
- The Trade: AMREP Corporation (NYSE:AXR) 10% owner Rainey Lancaster bought a total of 6,800 shares at an average price of $21.93. To acquire these shares, it cost around $149,120.
- What's Happening: Amrep, last month, reported a decline in quarterly sales.
- What AMREP Does: Amrep Corp through its subsidiaries is engaged in the Real estate business.
- 交易：AMREP 公司（紐約證券交易所代碼：AXR）10% 的所有者雷尼·蘭開斯特 共購買了6,800股股票 平均價格爲21.93美元。收購這些股票的成本約爲149,120美元。
- 發生了什麼：Amrep上個月報告了季度銷售額的下降。
- AMREP的所作所爲：Amrep Corp通過其子公司從事房地產業務。
Check This Out: Top 4 Tech And Telecom Stocks That May Crash In January
看看這個： 一月份可能暴跌的四大科技和電信股票